Childhood Absence Epilepsy Treatment Market Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026
Childhood Absence Epilepsy Treatment Market
Epilepsy is an illness that
affects a lot of people, particularly in developing nations. The prevalence and
incidence of epilepsy in children appear to be higher in rural areas of
underdeveloped countries and lower in industrialised economies. For instance,
the World Health Organization (WHO) estimates that in February 2018 over 80% of
epilepsy patients reside in low- and middle-income nations.
Genetic alterations and mutations
are the most common causes of the condition, which often manifests between the
ages of 5-8. The likelihood of misdiagnosis in childhood absence epilepsy,
particularly with attention deficit hyperactivity disorder, is increased by the
symptoms' closeness to those of other disorders. Ethosuximide, lamotrigine, and
valproic acid are a few of the commonly used medicines on the market. The use
of ethosuximide during treatment is among the most common because it is
effective in reducing common absence seizures.
The report carefully examines the
current medication pipelines of major manufacturers in the Childhood
Absence Epilepsy Treatment market. The study provides information on
numerous strategic measures they made to establish a foothold there. Teva
Pharmaceutical Industries Ltd., AbbVie, Inc., Insys Therapeutics, Inc.,
GlaxoSmithKline Plc, Pfizer, Inc., and Cavion, Inc. are a few of the companies
looking to increase their market share.
Comments
Post a Comment